The global viral vector and plasmid Deoxyribonucleic Acid (DNA) manufacturing market size was USD 1.3 Billion in 2022 and is expected to reach USD 8.07 Billion in 2032, and register a revenue CAGR of 22.5% during the forecast period. Prevalence of chronic diseases, rising demand for gene therapy, and development of genetic engineering technologies are major factors driving market revenue growth.
Gene treatments are becoming more popular due to their potential to treat a variety of illnesses, such as uncommon genetic disorders, malignancies, and infectious diseases. Plasmid DNA and viral vectors are needed for gene treatments in order to deliver therapeutic genes to target cells. As a result, there is high demand for the production of viral vectors and plasmid DNA, which is driving revenue growth of the market.
In addition, need for viral vectors and plasmid DNA has increased as a result of developments in genetic engineering methods such as CRISPR-Cas9. The market is expanding because need for high-quality viral vectors and plasmid DNA for their applications by these technologies.
Moreover, demand for viral vectors and plasmid DNA is being driven by the rising prevalence of chronic diseases such as cancer, Diabetes, and heart ailments. Gene therapy may be used to treat these disorders in a sophisticated manner, which is driving revenue growth of the market.
Revenue growth of the market for producing viral vectors and plasmid DNA is driven by governments and business entities investing more money in research and development. With the help of this funding, innovative and innovative technologies are being created that can create plasmid DNA and viral vectors of the highest caliber.
As different diseases call for particular kinds of viral vectors and plasmid DNA, the market is likewise seeing rising demand for these products. Manufacturers are placing a greater emphasis on creating customized items due to this tendency, which is driving revenue growth of the market.
However, high cost of production and strict regulatory requirements, among other things, are major factors, which could restrain revenue growth of the market. The labor-intensive and expensive process of producing viral vectors and plasmid DNA could hamper revenue growth of the market. Furthermore, tight regulatory requirements for the production and application of viral vectors and plasmid DNA could restrain revenue growth of the market to some extent.
Viral vectors and plasmid DNA make up the two main types of the global market for manufacturing viral vectors and plasmid DNA. Viral vectors accounted for a remarkably large revenue proportion of the overall market in 2023.
Because they can be used to transfer new genetic information into cells, viral vectors are frequently used in gene therapy. To treat or prevent diseases, therapeutic genes are delivered to cells using these vectors. Viral vectors have been utilised in numerous clinical studies to treat diseases like cancer, genetic abnormalities, and infectious diseases because of their high efficacy in delivering genes to cells.
Throughout the projection period, the plasmid DNA segment is anticipated to post the quickest revenue CAGR. A brief, circular bit of DNA called a plasmid is frequently employed in genetic engineering. These plasmids are frequently employed as a tool for DNA vaccinations, gene therapy, and molecular cloning. The creation of huge quantities of DNA that can be used for scientific or medical study is known as plasmid DNA manufacture.
It is anticipated that a number of factors, including the increased need for gene therapies, developments in Biotechnology, and rising investments in R&D activities, will propel the expansion of the viral vector and plasmid DNA manufacturing market. The rising incidence of diseases including cancer, genetic disorders, and infectious diseases is also anticipated to have an impact on the market.
Moreover, the development of cutting-edge technologies like CRISPR/Cas9 and other Genome Editing tools is anticipated to fuel market expansion in the next years. With the aid of these technologies, researchers may accurately alter the genes of living things, which may result in the creation of novel treatments for a number of ailments.
The development of the market for producing viral vector and plasmid DNA is also anticipated to be fueled by government efforts and funding schemes for R&D in the biotechnology sector. For instance, the National Institutes of Health (NIH) of the United States government has allotted a sizeable amount of money for research and development initiatives connected to genetic engineering and gene therapy.
By application, the global market for the production of viral vectors and plasmid DNA has been divided into gene therapy, Vaccines, Cell Therapy, and others. Gene therapy is one of these categories that has recently contributed significantly to market revenue.
In order to treat or prevent an illness, a patient's cells may be subjected to a technique called gene therapy. The capacity of viral vectors and plasmid DNA to effectively carry genetic material to the target cells has led to an increase in their application in gene therapy. As a result, the gene therapy market segment now accounts for a sizeable portion of global sales in the industry that produces viral vectors and plasmid DNA.
Throughout the anticipated period, revenue growth is also anticipated to be driven by the vaccines segment. Due to their capacity to elicit potent immune responses, viral vectors and plasmid DNA are increasingly being used in the development of vaccines. As a result, numerous DNA- and viral vector-based vaccines that have been licenced for use against a number of diseases were developed. The COVID-19 pandemic has increased the market for DNA- and viral-based vaccinations, and it is anticipated that this trend will continue throughout the prediction period.
The forecast term is expected to see rapid expansion in the cell therapy market. In cell therapy, viral vectors and plasmid DNA have been used to genetically alter cells to treat a variety of illnesses, including cancer and genetic abnormalities. In preclinical and clinical research, the use of viral vectors and plasmid DNA in cell therapy has yielded encouraging results, which has led to a rise in demand for these products in the global viral vector and plasmid DNA manufacturing market.
Throughout the forecast period, it is also anticipated that other uses of viral vectors and plasmid DNA, such as research and development and diagnostics, would help drive revenue growth in the global viral vector and plasmid DNA manufacturing market.
Technology advancements in the production of viral vectors and plasmid DNA, rising funding for gene therapy research and development, growing acceptance of gene therapy and cell therapy for the treatment of diseases, and an increase in the prevalence of chronic and genetic diseases are anticipated to be the market's primary revenue growth drivers. Moreover, the market is anticipated to grow due to the rising need for DNA- and viral vector-based vaccinations, particularly in developing nations.
Throughout the forecast period, revenue growth is anticipated to be fueled by government initiatives to assist the development and production of gene therapies and cell therapies, as well as the rising number of clinical studies for these treatments.
The Viral Vector and Plasmid DNA Manufacturing Market was dominated by the North American market in terms of revenue in 2021. The area boasts a strong healthcare infrastructure, a sizable patient base, and substantial funding for biotechnology and pharmaceutical research. Due to this, there is a strong demand for vaccinations and gene therapies, which in turn raises the need for viral vector and plasmid DNA production. Leading biotech and pharmaceutical firms' presence in the area has also contributed to the market's expansion. The adoption of cutting-edge technology and the rising volume of clinical trials being undertaken in the area are also fueling the demand for viral vector and plasmid DNA manufacture.
Throughout the anticipated period, the Europe market is anticipated to increase at a significant rate. Together with a rising need for vaccinations and gene therapies, the region is home to many biotech and pharmaceutical firms. Also, the region is seeing an increase in the number of partnerships and collaborations between research institutions and biotech firms, which is fueling demand for the production of viral vectors and plasmid DNA. The market expansion is also being aided by the favourable regulatory environment provided by the European Union and the availability of funds for R&D efforts. Additionally, it is anticipated that the region's growing elderly and chronic disease populations would increase demand for gene therapies, propelling the expansion of Europe's viral vector and plasmid DNA production industry.
The demand for cutting-edge gene treatments and vaccines, as well as rising investments in biotechnology research, are likely to fuel considerable growth in the Asia-Pacific market during the forecast period. A big patient population and well-established biotech companies in nations like China, Japan, and South Korea are driving up demand for the production of viral vectors and plasmid DNA. Also, the region is seeing an increase in partnerships and collaborations among biotech firms, academic institutions, and governmental organisations, which is fueling the market's expansion. Low manufacturing costs and a favourable regulatory climate in the area are also contributing to the market's expansion.
Some of the major players in this market include:
New Product Launches:
Segments Covered in the Report: